11.78
+0.07(+0.60%)
Currency In USD
| Previous Close | 11.71 |
| Open | 11.69 |
| Day High | 11.96 |
| Day Low | 11.61 |
| 52-Week High | 21.44 |
| 52-Week Low | 10.52 |
| Volume | 13,258 |
| Average Volume | 30,994 |
| Market Cap | 154.84M |
| PE | -14.54 |
| EPS | -0.81 |
| Moving Average 50 Days | 12.34 |
| Moving Average 200 Days | 13.81 |
| Change | 0.07 |
If you invested $1000 in Greenwich LifeSciences, Inc. (GLSI) since IPO date, it would be worth $2,356 as of March 13, 2025 at a share price of $11.78. Whereas If you bought $1000 worth of Greenwich LifeSciences, Inc. (GLSI) shares 3 years ago, it would be worth $574.63 as of March 13, 2025 at a share price of $11.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
GlobeNewswire Inc.
Feb 10, 2025 11:00 AM GMT
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
GlobeNewswire Inc.
Jan 29, 2025 11:00 AM GMT
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
GlobeNewswire Inc.
Jan 27, 2025 11:00 AM GMT
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno